Form 4: Serina Therapeutics Director Gregory Bailey Buys and Disposes of Shares
SEC Form 4 Filing
Gregory Bailey, a director at Serina Therapeutics, recently engaged in transactions involving the company's common stock, acquiring 9,019 shares and disposing of 13,828 shares on May 28, 2024.
Summary
- On May 28, 2024, Gregory Bailey, a director of Serina Therapeutics, executed transactions involving the company's common stock.
- Bailey acquired 9,019 shares of common stock at a price of $9.5 per share.
- Simultaneously, Bailey disposed of 13,828 shares of common stock.
- Following these transactions, the filing indicates Bailey's beneficial ownership of Serina Therapeutics' securities.
Sentiment
Score: 5
Explanation: This is a neutral report on stock transactions by a company director. It doesn't inherently indicate positive or negative sentiment.
Industry Context
Form 4 filings are standard practice for reporting transactions by company insiders, providing transparency to the market regarding their trading activities.
Stakeholder Impact
- Shareholders may be interested in the trading activity of company insiders as it can provide insights into their perspective on the company's value and prospects.
Key Dates
| Date | Description |
|---|---|
| 05/28/2024 | Date of stock acquisition and disposition by Gregory Bailey |
| 05/29/2024 | Date of signature on the SEC Form 4 |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.